Education
About Us
Working with TipRanks
Follow Us
Anteris Technologies Global Corp. (AVR)
NASDAQ:AVR
AVR Stock Chart & Stats
$6.20
-$0.12(-2.09%)
At close: 4:00 PM EST
$6.20
-$0.12(-2.09%)
Day’s Range― - ―
52-Week Range$2.34 - $8.08
Previous Close$5.88
Volume157.53K
Average Volume (3M)151.40K
Market Cap
$615.48M
Enterprise Value$217.79M
Total Cash (Recent Filing)$12.58M
Total Debt (Recent Filing)$2.28M
Price to Earnings (P/E)―
Beta1.96
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding97,232,056
10 Day Avg. Volume215,658
30 Day Avg. Volume151,395
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)-1.27K
Price to Sales (P/S)61.50
P/FCF Ratio-1.48
Enterprise Value/Market Cap0.35
Enterprise Value/Revenue113.85
Enterprise Value/Gross Profit162.05
Enterprise Value/Ebitda-2.36
Forecast
1Y Price Target
$18.50Price Target Upside198.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strategic Financing & Medtronic AlignmentThe $320M gross raise, including a Medtronic strategic equity stake, materially extends runway to execute the PARADIGM pivotal trial, expand manufacturing, and support commercialization. The partnership also brings industry credibility and potential commercial collaboration that strengthens execution capacity over the medium term.
Pivotal Randomized PARADIGM TrialRunning a large randomized head‑to‑head pivotal study creates a durable clinical evidence pathway that can influence regulatory outcomes, reimbursement decisions, and physician adoption. Positive RCT results would materially improve competitive positioning and long‑term commercial prospects in structural heart markets.
Improved Product-level Gross MarginsA ~70% gross margin indicates favorable unit economics for DurAVR and suggests manufacturing and product cost advantages at the device level. If scaled with growing volume, this margin profile can support sustainable operating leverage and profitability once commercial adoption accelerates.
Bears Say
Declining Revenue TrendSustained revenue decline erodes the company’s ability to absorb fixed costs and demonstrates limited commercial traction to date. Without meaningful revenue inflection from successful trial outcomes and commercialization, operating losses will remain structurally large and constrain organic growth funding.
Severe Cash Burn And Negative FCFConsistent, large negative operating and free cash flow drives reliance on external capital to fund trials, manufacturing scale-up and operations. This sustained cash burn increases execution risk if capital markets tighten, and raises the likelihood of future dilutive financings that affect long‑term shareholder value.
Balance Sheet Deterioration And Dilution RiskNegative equity signals weakened financial flexibility and higher recapitalization risk, constraining strategic options and borrowing capacity. While the Medtronic investment provides capital, attendant investor rights and participation terms can limit future governance and capital‑raising freedom, a structural governance constraint.
Anteris Technologies Global Corp. News
AVR FAQ
What was Anteris Technologies Global Corp.’s price range in the past 12 months?
Anteris Technologies Global Corp. lowest stock price was $2.34 and its highest was $8.08 in the past 12 months.
What is Anteris Technologies Global Corp.’s market cap?
Anteris Technologies Global Corp.’s market cap is $615.48M.
When is Anteris Technologies Global Corp.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Anteris Technologies Global Corp.’s earnings last quarter?
Currently, no data Available
Is Anteris Technologies Global Corp. overvalued?
According to Wall Street analysts Anteris Technologies Global Corp.’s price is currently Undervalued.
Does Anteris Technologies Global Corp. pay dividends?
Anteris Technologies Global Corp. does not currently pay dividends.
What is Anteris Technologies Global Corp.’s EPS estimate?
Anteris Technologies Global Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Anteris Technologies Global Corp. have?
Anteris Technologies Global Corp. has 97,232,056 shares outstanding.
What happened to Anteris Technologies Global Corp.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Anteris Technologies Global Corp.?
Currently, no hedge funds are holding shares in AVR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Anteris Technologies Global Corp. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.50 (198.39% Upside)
$18.50 (198.39% Upside)
Hedge Fund Trend
Decreased
By 29.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $28.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 30.2%
Last 30 Days ▲ 30.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-14.53%
12-Months-Change
Fundamentals
Return on Equity
-2462.70%
Trailing 12-Months
Asset Growth
-9.61%
Trailing 12-Months
Company Description
Anteris Technologies Global Corp.
Anteris Technologies Global Corp., a structural heart company, discovers, develops, and commercializes medical devices to enhance the quality of life for patients with aortic stenosis. Its lead product candidate is the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also devlops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. was incorporated in 1999 and is based in Toowong, Australia.
AVR Stock 12 Month Forecast
Average Price Target
$18.50
▲(198.39% Upside)
Technical Analysis
Anika Therapeutics
―
Apyx Medical
―
Inogen
―
Treace Medical Concepts
―
Rapid Micro Biosystems
―
Ownership Overview
33.07% Insiders
3.48% Mutual Funds
31.12% Other Institutional Investors
26.96% Public Companies and
Individual Investors